SecBot SecBot
8-K ·Filed Apr 6, 2026

IBRX

ImmunityBio, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed7mo ago SEC0001193125-26-142932
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor for any follow-up from the FDA, as regulatory compliance issues in biotech can escalate. While the immediate risk appears mitigated by the company's response, continued scrutiny could impact investor sentiment or future promotional strategies.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.08
T+0 close · Apr 6, 2026 · via day close
Latest settled
+29.94%
T+60 · $9.20
Vs SPY
+16.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $7.08entry
  2. T+1 · 7mo ago −3.11%α −3.17% · $6.86
  3. T+5 · 7mo ago +3.11%α −1.03% · $7.30
  4. T+20 · 7mo ago +4.94%α −4.04% · $7.43
  5. T+60 · 5mo ago +29.94%α +16.47% · $9.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImmunityBio submitted a comprehensive response to an FDA warning letter regarding promotional materials for its drug ANKTIVA, confirming a cited television ad was never aired and removing a podcast under review. The company is implementing enhanced compliance measures, including executive training and external oversight.

Key Facts

  • FDA issued a Warning Letter on March 13, 2026, concerning promotional materials for ANKTIVA.
  • ImmunityBio confirmed the cited television advertisement was never broadcast or disseminated.
  • The company removed the identified podcast from its website and requested removal from third-party platforms.
  • Corrective actions include mandatory executive training, expanded Promotional Review Committee (PRC) protocols, and engagement of external regulatory counsel.
  • The statements in question were made during a podcast by Founder Dr. Patrick Soon-Shiong and were described as aspirational and forward-looking.

Financial Impact

No direct financial impact disclosed. No fines, penalties, or material financial adjustments were mentioned.

Risk Factors

  • Potential for further FDA action if compliance concerns are not fully resolved.
  • Reputational risk from regulatory scrutiny, which could affect physician or patient confidence in the company or its product.
  • Risk of future non-compliance if internal controls are not effectively strengthened.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-142932
Document: d70606dex991.htm0001193125-26-142932
Document: 0001193125-26-142932-index-headers.html0001193125-26-142932
Document: 0001193125-26-142932-index.html0001193125-26-142932
Document: 0001193125-26-142932.txt0001193125-26-142932

Track record

11 reports on IBRX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.12% at T+60 after the Apr 9, 2026 report. 2 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
  2. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
  3. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
  4. Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
  5. Aug 4, 202614w ago 8-K Neutral 5/10 Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
  6. Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
  7. Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
  8. May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
  9. Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
  10. Apr 6, 202632w ago 8-K Neutral 4/10 Viewing Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (9h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026